3 unknown, 1 recruiting, 1 terminated. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Ced Service GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients With Mild to Moderately Active Ulcerative Colitis Low-Dose CICR-NAM, High-Dose CICR-NAM, 0 g/d CICR-NAM (blinded) - Ulcerative Colitis, Unspecified | Phase 2 / Phase 3 | Recruiting | University Hospital Schleswig-Holstein | 459 | 2024-09-12 | 2026-10-22 |
| TARGET Registry A Project of the German Network for Intestinal Diseases in Cooperation With Other Corporate Partners No intervention, only standard care - Crohn Disease, Ulcerative Colitis | Unknown | Ced Service GmbH | 4400 | 2019-10-01 | 2019-07-29 | |
| Tofacitinib Registry of Patients With Ulcerative Colitis in Germany Colitis, Ulcerative, Biologics | Terminated | Ced Service GmbH | 50 | 2019-08-01 | 2021-10-08 | |
| Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany vedolizumab - Inflammatory Bowel Diseases, Treatment | Unknown | Ced Service GmbH | 2500 | 2017-10-02 | 2017-12-18 | |
| Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra - Crohn Disease | Unknown | Ced Service GmbH | 900 | 2017-04-15 | 2018-07-13 |
Colitis, Ulcerative (4) · Crohn Disease (3) · Inflammatory Bowel Diseases (2) · Intestinal Diseases (1)
vedolizumab (2) · Adalimumab (1) · CT-P13 (1) · Infliximab (1) · Ustekinumab (1)
Germany (4)
Bernd Bokemeyer, PD Dr. med. (1) · Sandra Plachta-Danielzik, PD Dr. (1) · Stefan Schreiber, Prof. Dr. Dr. hc. (1)